Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis
Kymab Announces Positive Phase 2a Results for KY1005 in Moderate to Severe Atopic Dermatitis KY1005 met both primary end points demonstrating: A clinically meaningful improvement in disease activity compared to placebo, as measured by percentage of change …